| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.80 [0.65, 0.98] | | < 1 | | 67% | 4 studies (4/-) | 98.5 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.68 [0.57, 0.81] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| PFS (extension) | 0.61 [0.53, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.65 [0.51, 0.84] | | < 1 | | 67% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| DCR | 1.19 [0.86, 1.63] | | > 1 | | 0% | 1 study (1/-) | 85.6 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.78 [0.78, 4.03] | | > 1 | | 91% | 4 studies (4/-) | 91.5 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.96 [0.55, 7.07] | | < 1 | | 0% | 1 study (1/-) | 15.2 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.99 [0.66, 1.47] | | < 1 | | 0% | 1 study (1/-) | 52.2 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 0.65 [0.46, 0.92] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 1.74 [1.24, 2.44] | | < 1 | | 64% | 4 studies (4/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 1.22 [0.66, 2.26] | | < 1 | | 87% | 4 studies (4/-) | 26.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.78 [0.43, 7.37] | | < 1 | | 0% | 3 studies (3/-) | 21.3 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.28 [0.72, 2.27] | | < 1 | | 74% | 3 studies (3/-) | 20.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.23 [1.51, 3.30] | | < 1 | | 0% | 3 studies (3/-) | 0.0 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.63 [0.16, 16.15] | | < 1 | | 0% | 2 studies (2/-) | 33.9 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 1.16 [0.16, 8.29] | | < 1 | | 0% | 2 studies (2/-) | 44.1 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Chills TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.55 [0.19, 1.58] | | < 1 | | 80% | 4 studies (4/-) | 86.5 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.85 [0.06, 55.43] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.01 [0.53, 1.93] | | < 1 | | 48% | 4 studies (4/-) | 48.9 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.70 [0.08, 6.00] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.84 [0.10, 6.86] | | < 1 | | 86% | 2 studies (2/-) | 56.5 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.64 [0.17, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 74.9 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.23 [0.51, 2.94] | | < 1 | | 73% | 2 studies (2/-) | 32.1 % | low | not evaluable | high | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.64 [0.90, 7.72] | | < 1 | | 0% | 4 studies (4/-) | 3.9 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 2.78 [0.15, 52.88] | | < 1 | | 0% | 1 study (1/-) | 25.1 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 6.01 [0.30, 120.38] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.89 [0.40, 1.97] | | < 1 | | 0% | 4 studies (4/-) | 61.5 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.26 [0.22, 7.29] | | < 1 | | 0% | 4 studies (4/-) | 39.8 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.10 [0.19, 6.17] | | < 1 | | 40% | 4 studies (4/-) | 45.8 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.32 [0.26, 6.75] | | < 1 | | 45% | 4 studies (4/-) | 37.0 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.94 [0.15, 5.80] | | < 1 | | 0% | 3 studies (3/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 0.70 [0.08, 6.00] | | < 1 | | 0% | 2 studies (2/-) | 62.8 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.63 [0.29, 9.28] | | < 1 | | 0% | 3 studies (3/-) | 29.0 % | some concern | not evaluable | moderate | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.72 [0.08, 6.18] | | < 1 | | 0% | 3 studies (3/-) | 61.7 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.91 [0.21, 3.89] | | < 1 | | 0% | 4 studies (4/-) | 55.0 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.87 [0.57, 6.11] | | < 1 | | 0% | 4 studies (4/-) | 15.0 % | low | not evaluable | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 1.46 [0.58, 3.68] | | < 1 | | 0% | 2 studies (2/-) | 21.3 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.72 [0.08, 6.18] | | < 1 | | 0% | 3 studies (3/-) | 61.7 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.34 [0.01, 17.42] | | < 1 | | 0% | 1 study (1/-) | 69.9 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 1.37 [0.11, 17.90] | | < 1 | | 0% | 2 studies (2/-) | 40.6 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 1.03 [0.21, 5.19] | | < 1 | | 0% | 1 study (1/-) | 48.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.95 [0.30, 3.03] | | < 1 | | 0% | 1 study (1/-) | 53.7 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.34 [0.07, 1.70] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.69 [0.02, 20.65] | | < 1 | | 0% | 1 study (1/-) | 58.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.03 [0.21, 5.19] | | < 1 | | 0% | 1 study (1/-) | 48.3 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.83 [0.34, 2.05] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.96 [0.34, 2.73] | | < 1 | | 0% | 1 study (1/-) | 52.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.71 [0.31, 1.62] | | < 1 | | 0% | 1 study (1/-) | 79.0 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.45 [0.10, 2.06] | | < 1 | | 0% | 1 study (1/-) | 84.7 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.68 [0.17, 2.78] | | < 1 | | 0% | 1 study (1/-) | 70.2 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.38 [0.06, 30.82] | | < 1 | | 0% | 1 study (1/-) | 42.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.80 [0.20, 3.14] | | < 1 | | 0% | 1 study (1/-) | 62.5 % | NA | not evaluable | | non important | - |
